Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGILENT TECHNOLOGIES, INC.

(A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

10/13/2021 | 04:16pm EST

Agilent Technologies Inc. announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered. This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was developed in collaboration with Eli Lilly and Company. Understanding the risk of recurrence in EBC is vital for informing disease management, as identifying patients at high risk can provide clarity for patients as well as facilitate treatment decisions to potentially improve outcomes. Conventional methods for evaluating the risk of recurrence in EBC are based on staging and are performed according to standard clinical and pathological features of the disease. However, these standard features may not capture the full risk of recurrence for individuals with EBC. The American Joint Committee on Cancer has identified the Ki-67 biomarker as Level of Evidence III in diagnosing EBC due to its association with cellular proliferation. Ki-67 is thus an important component of comprehensive risk assessment, but it has been inconsistently applied in the past. This approval builds on Agilent's previous successes in expanding the clinical applicability of therapeutic biomarker analysis, further cementing the company's position as a provider of diagnostic assays that deliver high quality and ease of implementation.


ę S&P Capital IQ 2021
All news about AGILENT TECHNOLOGIES, INC.
11/23Agilent to Present at Evercore ISI Virtual Healthcare Conference
BU
11/23Stifel Adjusts Price Target for Agilent Technologies to $169 From $162, Maintains Hold ..
MT
11/23SVB Leerink Adjusts Agilent Technologies' Price Target to $175 from $170, Keeps Outperf..
MT
11/23Health Care Stocks Flat Ahead of Tuesday's Opening Bell
MT
11/22AGILENT TECHNOLOGIES : Prepared Remarks (opens in new window)
PU
11/22AGILENT : Fiscal Q4 Earnings Snapshot
AQ
11/22Agilent Technologies Fiscal Q4 non-GAAP EPS, Revenue Rise
MT
11/22AGILENT TECHNOLOGIES : Reports Fourth-Quarter and Fiscal Year 2021 Financial Results - For..
PU
11/22Earnings Flash (A) AGILENT TECHNOLOGIES Posts Q4 Revenue $1.66B, vs. Street Est of $1.6..
MT
11/22Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results
BU
More news
Analyst Recommendations on AGILENT TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2021 6 318 M - -
Net income 2021 1 075 M - -
Net Debt 2021 1 485 M - -
P/E ratio 2021 43,6x
Yield 2021 0,50%
Capitalization 46 035 M 46 035 M -
EV / Sales 2021 7,52x
EV / Sales 2022 6,95x
Nbr of Employees 17 000
Free-Float 100,0%
Chart AGILENT TECHNOLOGIES, INC.
Duration : Period :
Agilent Technologies, Inc. Technical Analysis Chart | A | US00846U1016 | MarketScreener
Technical analysis trends AGILENT TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 152,07 $
Average target price 173,80 $
Spread / Average Target 14,3%
EPS Revisions
Managers and Directors
Michael R. McMullen President, Chief Executive Officer & Director
Robert W. McMahon Chief Financial Officer & Senior Vice President
Koh Boon Hwee Non-Executive Chairman
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Katharine Knobil Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGILENT TECHNOLOGIES, INC.29.10%46 307
THERMO FISHER SCIENTIFIC35.90%249 432
DANAHER CORPORATION42.02%225 435
INTUITIVE SURGICAL, INC.24.47%121 253
SIEMENS HEALTHINEERS AG52.88%80 680
EDWARDS LIFESCIENCES CORPORATION25.50%71 480